INT96579

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.55
Pain Relevance 1.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (MMP9) extracellular space (MMP9) extracellular region (MMP9)
proteinaceous extracellular matrix (MMP9) extracellular matrix organization (MMP9) protein complex (MMP9)
Anatomy Link Frequency
PSP 2
MMP9 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 69 100.00 Very High Very High Very High
Inflammation 18 100.00 Very High Very High Very High
cytokine 3 89.28 High High
Snapping jaw 1 76.76 Quite High
cINOD 5 75.00 Quite High
Bile 9 5.00 Very Low Very Low Very Low
Hippocampus 4 5.00 Very Low Very Low Very Low
Acupuncture 3 5.00 Very Low Very Low Very Low
Bioavailability 3 5.00 Very Low Very Low Very Low
imagery 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 26 100.00 Very High Very High Very High
Corneal Neovascularization 3 100.00 Very High Very High Very High
Cancer 110 99.88 Very High Very High Very High
Necrosis 10 99.60 Very High Very High Very High
Burns 14 97.68 Very High Very High Very High
Inflammatory Bowel Disease 2 95.80 Very High Very High Very High
Wound Healing 5 94.28 High High
Apoptosis 38 93.24 High High
Nasopharynx Cancer 4 91.88 High High
Fibrosarcoma 4 86.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of MMP-2 and MMP-9 activities was partly prevented by the addition of 1,10 phenanthroline, a divalent metal chelator, to the amalgam conditioned buffers.
Negative_regulation (prevented) of Negative_regulation (Inhibition) of MMP-9
1) Confidence 0.40 Published 2001 Journal Biomaterials Section Abstract Doc Link 11426881 Disease Relevance 0.23 Pain Relevance 0.23
Furthermore, flurbiprofen was shown to induce the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), an inhibitor of MMP-9.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of MMP-9 associated with metalloproteinase
2) Confidence 0.35 Published 2009 Journal Arch. Biochem. Biophys. Section Abstract Doc Link 19501039 Disease Relevance 0.33 Pain Relevance 0.28
Their findings clearly show that application of PSP has reduced several parameters related to CNV and/or inflammation including the downregulation of MMP-2 and MMP-9 [77].
Negative_regulation (reduced) of Negative_regulation (downregulation) of MMP-9 in PSP associated with corneal neovascularization and inflammation
3) Confidence 0.12 Published 2010 Journal Biochemistry Research International Section Body Doc Link PMC3004377 Disease Relevance 1.19 Pain Relevance 0.10
It was postulated that the observed down-regulation of matrix metalloproteinase-9 was due to inhibition of granulocytemacrophage colonystimulating factor (GM-CSF) production which resulted in decreased binding activity of NF-kB and AP-1 transcription factors.
Negative_regulation (down) of Negative_regulation (regulation) of matrix metalloproteinase-9 associated with metalloproteinase
4) Confidence 0.05 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852855 Disease Relevance 0.87 Pain Relevance 0.09
1 orally significantly reduced inflammatory changes, partly through suppression of matrix metalloproteinase (MMP-9), tumour necrosis factor (TNF), and interleukin-?
Negative_regulation (reduced) of Negative_regulation (suppression) of MMP-9 associated with necrosis, inflammation, cancer and metalloproteinase
5) Confidence 0.03 Published 2010 Journal Advances in Pharmacological Sciences Section Body Doc Link PMC3003978 Disease Relevance 1.92 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox